Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: An approach is provided for a parallel printing solution wherein one of a plurality of printing devices is designated a “master” device and receives print data, portions of which are then transmitted to the remainder of printing devices for processing according to instructions from the master device. According to one embodiment of the invention, a user defines certain parameters and administrative criteria at a workstation, from which the user sends print data to the master device. In one embodiment, based upon user-defined parameters and independently acquired information, the master device divides the print data into print jobs and sends the appropriate print data to the plurality of print devices for processing.

Abstract: A display panel for a LCD device includes a substrate, a plurality of thin film transistors formed on the substrate, a passivation layer formed on the thin film transistors, a plurality of reflective patterns formed on the passivation layer, transparent electrodes formed on the reflective patterns, and reflective films formed on the transparent electrode. The reflective patterns and the reflective films are formed in a reflective area of the passivation layer. The reflective patterns are formed by position transition of two polymer films having different polarities. The display panel having the reflective patterns increase light reflectance and reduce cost for manufacturing an LCD.

Abstract: A method of driving and a liquid crystal display that are adaptive for preventing a motion blur phenomenon inserting a black data without reducing a data charging time are disclosed. In the liquid crystal display, a first gate line supplies a first scanning signal. A second gate line supplies a second scanning signal. A data line supplies a data signal. A common line supplies a common voltage. A first thin film transistor supplies the data signal in response to the first scanning signal. In a liquid crystal cell, a pixel electrode is connected to the first thin film transistor and a common electrode is connected to the common line. A second thin film transistor supplies the common voltage to the pixel electrode in response to the second scanning signal.

Abstract: A driving apparatus and method of an LCD device improves the brightness and the contrast ratio of an image. The driving apparatus includes an LCD panel for displaying an image corresponding to a data signal. A data driver supplies the data signal to the LCD panel. A gate driver supplies a scan signal to the LCD panel. A picture quality improving unit generates a histogram by dividing brightness components of input data into levels, generates data with an extended contrast ratio, and then generates a brightness control signal according to the average value of the histogram. A timing controller supplies reordered data, and controls the data driver and the gate driver. A backlight provides light to the LCD panel. An inverter drives the backlight based on the brightness control signal.

Abstract: A semiconductor package may include a printed circuit board having a conductive bump pad. At least one semiconductor chip may be electrically connected to the printed circuit board. A lead free conductive bump may be mounted on the conductive bump pad. The lead free conductive bump may include no more than about 0.3% by weight of copper. The lead free conductive bump may include about 3.0% to about 4.0% by weight of silver, about 0.1% to about 0.3% by weight of copper and about 95.7% to about 96.9% by weight of tin.

Abstract: A plasma display device and a driving method thereof. A sustain discharge before a reset period for initializing a cell which is sustain discharged in a previous subfield is generated as a weak discharge rather than a strong discharge. By generating a weak sustain discharge, the amount of wall charge formed in the exterior area of electrodes may be reduced. As a result, in the subsequent reset period, the wall charge can be controlled to be appropriate for addressing while preventing misfiring and low discharge.

Abstract: A radio frequency identification (RFID) tag based object position tracking apparatus and method are provided. The apparatus includes a position recognizer including at least one radio frequency identification unit for reading information data on an object through a sensor; and a path analyzing and processing unit for allocating each unique coordinates to the radio frequency identification units based on a relative position in a space where a position recognizer is disposed and recognizing the position of the object and analyzing the path based on the object information data received by the sensor in the radio frequency identification unit corresponding to the unique coordinate. Thus, it is possible to track the path of an object with a low density of RFID tags.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Abstract: A sustain or scan electrode driver for a plasma display device including a power recovery circuit, a voltage storage circuit, and a switching circuit. Power recovery is achieved by a coupling a power source at a minus sustain voltage to the sustain or scan electrode driver circuit that includes a capacitor and an inductor for creating resonance with the panel capacitor and recovering the power used in sustain discharge. Power loss of switches used in the driver circuit may be reduced and power recovery efficiency may be increased by using an additional capacitor in the driver circuit that maintains terminals of the switch at a predetermined level.

Abstract: A power supply that is employable by a plasma display device for generating and supplying a plurality of voltages, the power supply including a first power source generating and supplying a first voltage, a transistor having a drain electrically coupled to the first power source, a first resistor having a first end coupled to the first power source and a second end electrically coupled to a gate of the transistor, a second resistor having a first end coupled to the second end of the first resistor and a second end electrically coupled to a second power source supplying a second voltage that is lower than the first voltage, and a capacitor having a first end coupled to a source of the transistor and a second end electrically coupled to the second power source. The coupling of the first end of the capacitor to the source of the transistor may form a third voltage supply node having the third voltage when the capacitor is charged.

Abstract: A method for driving a flat panel display to improve an image quality and a lifetime of the flat panel display is disclosed. The method for driving the flat panel display includes the steps of: a) storing electric-charges contained in a parasitic capacitor of a data line and a pixel-storage capacitor (Cst) in each pixel via a pixel transistor connected to the data line, which enters a floating state during a predetermined time other than a light-emitting time caused by a data-current writing operation, until a current voltage reaches a threshold voltage of the pixel transistor; and b) performing the writing of a data current corresponding to a pixel to be driven by the data line via the pixel transistor, such that the flat panel display emits light.

Abstract: In accordance with an embodiment of the present invention, control device and method are disclosed for reducing unnecessary data backup and restoring operations and increasing data read and write speed in a flash memory. The method includes writing data received from the host system to the flash memory; moving valid data in the basic block to the first link block when a use ratio of the first link block is greater than a reference value; and moving valid data in the first link block to the second link block when a use ratio of the first link block is less than the reference value.

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract: The present invention relates to a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant, comprising one or more amino acid modifications selected from the group consisting of M160N, A195N, T243N, E265N, Y299T, F331T and Q346N, is additionally glycosylated, and a gene encoding the same.

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract: A shadow mask for a Cathode Ray Tube (CRT) which achieves a high brightness and white uniformity by minimizing light emission of incorrect colors, includes: an effective screen portion with a plurality of beam passage holes arranged in a predetermined pattern and a non-holed portion surrounding the effective screen portion with no beam passage holes. The beam passage holes have a large-sized hole portion on a side facing a panel of the CRT and a small-sized hole portion that is smaller than the large-sized hole portion on a side facing an electron gun are selected such.